Celgene Corporation (CELG) : The value of composite uptick trades was $64.99 million, whereas, the value of composite downtick trades was $70.45 million. The uptick to downtick ratio stood at 0.92 with a negative money flow of ($5.46) Million during Tuesdays trading session. The block trades money flow was negative ($3.9 million).The uptick to the downtick ratio of 1.35 in block trades signals that the large investors have utilized the rise in the stock to sell.The uptick transaction value stood at $15.16 million. The transaction of the trades on downticks amounted to $11.26 million, which confirms investors selling on the strength of price. Celgene Corporation (CELG) gained 12 cents at $103.53, an increase of 0.12% over the previous days close.
The company Insiders own 0.97% of Celgene Corporation shares according to the proxy statements. In the past twelve weeks, the net percent change held by company insiders has changed by -6.26% . Institutional Investors own 81.32% of Celgene Corporation shares. During last six month period, the net percent change held by insiders has seen a change of -7.12%. In an insider trading activity,The director officer (see remarks) of Celgene Corp /De/, Hugin Robert J sold 75,000 shares at $100.16 on June 20, 2016. The Insider selling transaction had a total value worth of $7,512,000. The Insider information was disclosed with the Securities and Exchange Commission in a Form 4 filing.
Shares of Celgene Corporation rose by 3.15% in the last five trading days and 0.49% for the last 4 weeks. Celgene Corporation has dropped 1.76% during the last 3-month period . Year-to-Date the stock performance stands at -13.65%.
Celgene Corporation (NASDAQ:CELG): The stock was completely flat for the day, closing at $103.41 on Tuesday. The flat closing masks the intraday volatility in the stock. After opening at $104.05, the stock touched an intraday high of $104.91 and a low of $103.26. Neither the bulls nor the bears asserted their supremacy at close, due to which the stock closed completely flat. The stock previously closed at $103.41. The total trading volume on Tuesday was 3,851,896.
Celgene Corporation (Celgene), together with its subsidiaries, is an integrated biopharmaceutical company engaged primarily in the discovery, development and commercialization of therapies for the treatment of cancer and inflammatory diseases through gene and protein regulation. The Companys primary commercial stage products include REVLIMID (lenalidomide), ABRAXANE, POMALYST/IMNOVID, VIDAZA, azacitidine for injection (generic version of VIDAZA), THALOMID (sold as THALOMID or Thalidomide Celgene outside the United States), OTEZLA (apremilast) and ISTODAX (romidepsin). Celgene is involved in research in a range of scientific areas designed to deliver therapies, targeting areas, including intracellular signaling pathways, protein homeostasis and epigenetics in cancer and immune cells, immunomodulation in cancer and autoimmune diseases, and therapeutic application of cell therapies.